Radioembolization-Induced Liver Disease
The aim of liver radioembolization is to deliver an effective dose of radiation to liver tumors while the nontumoral liver is only exposed to much lower, nonharmful dose. However, irradiation of the nontumoral compartment of the liver may produce cell damage that can translate into changes in laboratory tests or clinical signs of liver dysfunction. Radioembolization-induced liver disease has been recently described as a syndrome consisting in jaundice and ascites that appears 1–2 months after treatment in the absence of tumor progression or bile duct occlusion. This complication is extremely rare in the absence of cirrhosis or intense prior exposure to chemotherapeutic agents particularly if chemotherapy is continued immediately after radioembolization. Its incidence is likely to be lower than 10 % and it has a transient or stable course in most cases, but it may unusually lead to overt liver failure. A conservative dose prescription and the use of low-dose steroids or ursodeoxycholic acid have been suggested as prophylactic measures.
KeywordsExternal Beam Radiation Therapy Liver Volume Ursodeoxycholic Acid Normal Tissue Complication Probability Glass Microsphere
CIBEREHD is funded by Instituto de Salud Carlos III.
The authors wish to thank Paloma Sangro for her valuable work in the review of the literature and the preparation of the manuscript.
- Bilbao JI, Martino A, Luis E, Díaz-Dorronsoro L, Alonso-Burgos A, de la Martínez A, Cuesta A et al (2009) Biocompatibility, inflammatory response, and recannalization characteristics of nonradioactive resin microspheres: histological findings. Cardiovasc Intervent Radiol 32(4):727–736PubMedCentralPubMedCrossRefGoogle Scholar
- Carr BI (2004) Hepatic arterial90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 10(S2):S107–S110Google Scholar
- Cheng JC-H, Wu J-K, Huang C-M, Liu H-S, Huang DY, Cheng SH et al (2002) Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 54(1):156–162PubMedCrossRefGoogle Scholar
- Cheng JC-H, Wu J-K, Lee PC-T, Liu H-S, Jian JJ-M, Lin Y-M et al (2004) Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 60(5):1502–1509Google Scholar
- Chiesa C, Maccauro M, Romito R, Spreafico C, Pellizzari S, Negri A et al (2011) Need, feasibility and convenience of dosimetric treatment planning in liver selective internal radiation therapy with (90)Y microspheres: the experience of the National Tumor Institute of Milan. Q J Nucl Med Mol Imaging 55(2):168–197PubMedGoogle Scholar
- Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M et al (2008) Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres. Phys Med Biol 53(22):6591–6603PubMedCrossRefGoogle Scholar
- Gil-Alzugaray B, Chopitea A, Iñarrairaegui M, Bilbao JI, Rodriguez-Fraile M, Rodriguez J et al. (2012) Prognostic factors and prevention of radioembolization-induced liver disease. Hepatology. doi: 10.1002/hep.26191. [Epub ahead of print]
- Hall E (2006) Physics and chemistry of radiation absortion. In: Radiobiology for the Radiologist. Lippincott Williams & Wilkins, Philadelphia, pp 5–16Google Scholar
- Hendlisz A, Eynde MVD, Peeters M, Maleux G, Lambert B, Vannoote J et al (2010) Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 28(23):3687–3694PubMedCrossRefGoogle Scholar
- Jiang M, Fischman A, Nowakowski FS et al (2012) Segmental perfusion differences on paired Tc-99m macroaggregated albumin (MAA) hepatic perfusion imaging and Yttrium-90 (Y-90) bremsstrahlung imaging studies in SIR-Sphere radioembolization: associations with angiography. J Nucl Med Radiat Ther 3:122. doi: 10.4172/2155-9619.1000122
- Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C (2004) Pathologic response and microdosimetry of 90Y microspheres in man: Review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552–1563Google Scholar
- Mazzaferro V, Sposito C, Bhoori S, Romito R, Chiesa C, Morosi C et al (2012) Yttrium90 radioembolization for intermediate-advanced hepatocarcinoma: a phase II study. Hepatology n/a–n/aGoogle Scholar
- Nosher JL, Ohman-Strickland PA, Jabbour S, Narra V, Nosher B (2011) Changes in liver and spleen volumes and liver function after radioembolization with Yttrium-90 resin microspheres vol 22(12). JVIR. Elsevier Inc, pp 1706–1713Google Scholar
- Piana PM, Gonsalves CF, Sato T, Anne PR, McCann JW, Ad VB et al (2011) Toxicities after radioembolization with Yttrium-90 SIR-Spheres: incidence and contributing risk factors at a single center vol 22(10). JVIR. Elsevier Inc, pp 1373–1379Google Scholar
- Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology, vol 138(1). Elsevier Inc, pp 52–64Google Scholar
- Sangro B, Iñarrairaegui M, Bilbao JI (2012) Radioembolization for hepatocellular carcinoma. J Hepatol. European Association for the Study of the Liver 56(2):464–473Google Scholar
- Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J et al (2011b) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Intervent Radiol 35(5):1066–1073PubMedCrossRefGoogle Scholar
- Sharma RA, van Hazel GA, Morgan B, Berry DP, Blanshard K, Price D et al (2007) Radioembolization of liver metastases from colorectal cancer using Yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 25(9):1099–1106PubMedCrossRefGoogle Scholar
- van Hazel GA, Pavlakis N, Goldstein D, Olver IN, Tapner MJ, Price D et al (2009) Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using Yttrium-90 resin microspheres plus concomitant systemic Irinotecan chemotherapy. J Clin Oncol 27(25):4089–4095PubMedCrossRefGoogle Scholar